Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part Meeting Abstract

cited authors

  • Vaishampayan, Ulka N.; Sweis, Randy F.; Kilari, Deepak; Tarhini, Ahmad A.; Gainor, Justin F.; Barve, Minal A.; Sonpavde, Guru P.; McKean, Meredith; Park, David J.; Babu, Sunil; Ju, Yawen; Liu, Lan; Henry, Susan; Gan, Lu; Yap, Timothy A.

Publication Date

  • June 1, 2024

webpage

published in

category

volume

  • 42

issue

  • 16